Acrivon Therapeutics (ACRV) Total Debt to Capital

Acrivon Therapeutics relies on a highly specialized pipeline, which entails significant binary risks. The company dominates precision oncology through its AP3 technology, which adapts treatment to the protein composition of the tumor. The confirmed price history on this chart, where the indicator stands at 0.02, underscores the dependence on proteomic accuracy and ACR-368 test outcomes for selecting suitable patients.

The 0.02 metric measures financial leverage by comparing total liabilities to net assets to assess the capital structure's resilience to changes in borrowing costs. For Acrivon Therapeutics (ACRV), its outsourced research model makes reliance on external contractors critical for debt control, which is clearly evidenced by the history of the total debt-to-equity ratio.